Earnings Beat: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts [Yahoo! Finance]
Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Company Research
Source: Yahoo! Finance
Arcutis Biotherapeutics beat expectations with revenues of US$60m arriving 3.7% ahead of forecasts. The company also reported a statutory loss of US$3.78, 4.1% smaller than was expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. See our latest analysis for Arcutis Biotherapeutics Following the latest results, Arcutis Biotherapeutics' six analysts are now forecasting revenues of US$106.3m in 2024. This would be a major 78% improvement in revenue compared to the last 12 months. Losses are expected to hold steady at around US$2.35. Before this latest report, the consensus had been expecting revenues of US$85.7m and US$2.38 per share in losses. So there's definitely been
Show less
Read more
Impact Snapshot
Event Time:
ARQT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQT alerts
High impacting Arcutis Biotherapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ARQT
News
- Analysts Are Betting On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) With A Big Upgrade This Week [Yahoo! Finance]Yahoo! Finance
- Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory [Seeking Alpha]Seeking Alpha
- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at Needham & Company LLC from $16.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Topical Drug Delivery Market Size to Hit USD 229.91 Bn by 2031 [Yahoo! Finance]Yahoo! Finance
- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at Mizuho from $17.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
ARQT
Earnings
- 5/14/24 - Beat
ARQT
Sec Filings
- 5/20/24 - Form 4
- 5/17/24 - Form 144
- 5/17/24 - Form 144
- ARQT's page on the SEC website